AKTIVAX INC holds — across 1 federal awards. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.
THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOINJECTORS (AS A DRUG/DEVICE COMBINATION PRODUCT) TO TREAT ORGANOPHOSPHATE (OP) POISONING, INCLUDING NERVE AGENT
Current PoP ends Dec 31, 2026 (157 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Track recompete timing in SCOUT →AKTIVAX INC — — obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open AKTIVAX INC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →